FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2598833897> ?p ?o ?g. }

• W2598833897 abstract "Background Hypercholesterolemia plays a causal role in the development of cardiovascular diseases. Patients are affected differently. There is a lack of epidemiological data about the frequence and characteristics of patients in Germany, especially about those who do not respond sufficiently to high intensity statins with or without other lipid modifying therapies. Methods From more than 2.6 million patient records of office based general practitioners, patients with hypercholestrolemia and high cardiovascular risk, who do not reach their individual LDL-C goal despite a best supplied twelve month maximum lipid lowering therapy (MPR ≥ 80 %), were extracted from the database. Results 5791 909 statutorily insured German patients are extrapolated with hypercholesterolemia (95 % CI: 5787 368 - 5796 454). 602 133 (95 % CI: 600 620 - 603 650) patients with high cardiovascular risk were treated with high intensity lipid modifying therapy (medication possession rate ≥ 80 %) for at least 1 year. 49 406 (95 % CI: 48 972 - 49 843) of them got mono-therapy with high intensity statins, 51 869 (95 % CI: 51 425 - 52 317) received statins in any dose combined with other lipid lowering drugs. 79 848 (95 % CI: 79 313 - 80 385) high risk patients did not reach LDL-C < 70 mg/dl despite optimal lipid treatment. 12 808 (95 % CI: 12 589 - 13 030) high risk patients even had LDL-C values ≥ 130 mg/dl. Discussion To classify patient's therapy refractory, they must have maximal drug therapy over a sufficient period of time. Usually statins are prescribed as first line therapy. Due to adverse events or contraindications statins are often prescribed in submaximal doses. Therefore patients with statins at lower dose combined with another lipid lowering drug were also included in the analysis. For patients missing the LDL-C target of ≤ 130 mg/dl despite optimal lipid lowering therapy there is a high medical need for innovative therapies." @default.
• W2598833897 created "2017-04-07" @default.
• W2598833897 creator A5021777258 @default.
• W2598833897 creator A5026877938 @default.
• W2598833897 creator A5053278199 @default.
• W2598833897 creator A5056713659 @default.
• W2598833897 creator A5085902565 @default.
• W2598833897 date "2017-03-22" @default.
• W2598833897 modified "2023-09-27" @default.
• W2598833897 title "Sekundärdatenanalyse zur Ermittlung der Prävalenz von kardiovaskulären Hochrisiko-Patienten mit Hypercholesterinämie und therapierefraktärem Behandlungsverlauf" @default.
• W2598833897 cites W1240864963 @default.
• W2598833897 cites W131001499 @default.
• W2598833897 cites W1523152575 @default.
• W2598833897 cites W1920819302 @default.
• W2598833897 cites W1972661406 @default.
• W2598833897 cites W1993634977 @default.
• W2598833897 cites W2012161457 @default.
• W2598833897 cites W2028238607 @default.
• W2598833897 cites W2093954718 @default.
• W2598833897 cites W2110171695 @default.
• W2598833897 cites W2118310760 @default.
• W2598833897 cites W2133211347 @default.
• W2598833897 cites W2135128105 @default.
• W2598833897 cites W2145866410 @default.
• W2598833897 cites W2157838461 @default.
• W2598833897 cites W2165624352 @default.
• W2598833897 cites W2251889296 @default.
• W2598833897 cites W2498108824 @default.
• W2598833897 doi "https://doi.org/10.1055/s-0042-123977" @default.
• W2598833897 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/28329898" @default.
• W2598833897 hasPublicationYear "2017" @default.
• W2598833897 type Work @default.
• W2598833897 sameAs 2598833897 @default.
• W2598833897 citedByCount "1" @default.
• W2598833897 countsByYear W25988338972022 @default.
• W2598833897 crossrefType "journal-article" @default.
• W2598833897 hasAuthorship W2598833897A5021777258 @default.
• W2598833897 hasAuthorship W2598833897A5026877938 @default.
• W2598833897 hasAuthorship W2598833897A5053278199 @default.
• W2598833897 hasAuthorship W2598833897A5056713659 @default.
• W2598833897 hasAuthorship W2598833897A5085902565 @default.
• W2598833897 hasConcept C126322002 @default.
• W2598833897 hasConcept C197934379 @default.
• W2598833897 hasConcept C2778163477 @default.
• W2598833897 hasConcept C2778270857 @default.
• W2598833897 hasConcept C71924100 @default.
• W2598833897 hasConceptScore W2598833897C126322002 @default.
• W2598833897 hasConceptScore W2598833897C197934379 @default.
• W2598833897 hasConceptScore W2598833897C2778163477 @default.
• W2598833897 hasConceptScore W2598833897C2778270857 @default.
• W2598833897 hasConceptScore W2598833897C71924100 @default.
• W2598833897 hasLocation W25988338971 @default.
• W2598833897 hasLocation W25988338972 @default.
• W2598833897 hasOpenAccess W2598833897 @default.
• W2598833897 hasPrimaryLocation W25988338971 @default.
• W2598833897 hasRelatedWork W1985594325 @default.
• W2598833897 hasRelatedWork W2011252698 @default.
• W2598833897 hasRelatedWork W2023306345 @default.
• W2598833897 hasRelatedWork W2036748745 @default.
• W2598833897 hasRelatedWork W2374781999 @default.
• W2598833897 hasRelatedWork W2403511365 @default.
• W2598833897 hasRelatedWork W2785601178 @default.
• W2598833897 hasRelatedWork W2912636245 @default.
• W2598833897 hasRelatedWork W2920328101 @default.
• W2598833897 hasRelatedWork W3138912724 @default.
• W2598833897 isParatext "false" @default.
• W2598833897 isRetracted "false" @default.
• W2598833897 magId "2598833897" @default.
• W2598833897 workType "article" @default.